Ownership of Study Data. Subject to Principal Investigator’s right to use Study Data to publish the results of the Study (see Section 15, Publications), Pfizer is the exclusive owner of all Study Data.
Ownership of Study Data. BMS shall own the Study Data to the extent that it relates exclusively to the BMS Study Drug (“BMS Study Data”), and the Recipient shall own the Study Data to the extent that it relates exclusively to the Recipient Study Drug (“Recipient Study Data”). Both Parties shall jointly own any Study Data that does not relate exclusively to the Recipient Study Drug or the BMS Study Drug (“Combined Therapy Study Data”). Each Party shall, and does hereby, assign, and shall cause its Affiliates to so assign, to the other Party, without additional compensation, such right, title and interest in and to any Study Data as is necessary to fully effect the foregoing, and agrees to execute all instruments as may be reasonably necessary to effect same.
Ownership of Study Data. BMS shall own the Study Data to the extent that it relates exclusively to the BMS Compound (“BMS Study Data”), and Exelixis shall own the Study Data to the extent that it relates exclusively to the Exelixis Compound (“Exelixis Study Data”). The Parties shall jointly own (BMS to own 50% and Exelixis to own 50%) any Study Data that does not relate exclusively to the Exelixis Compound or the BMS Compound (“Combined Therapy Study Data”). Each Party shall, and does hereby, assign, and shall cause its Affiliates to so assign, to the other Party, without additional compensation, such right, title and interest in and to any Study Data as is necessary to fully effect the foregoing, and agrees to execute all instruments as may be reasonably necessary to effect same. 8.3
Ownership of Study Data. Corvus shall own all right, title and interest in and to Study Data from the single agent arm of the Study and such Study Data shall be deemed Corvus Confidential Information. Corvus and Genentech shall [***]. Genentech has the right to [***].
Ownership of Study Data. Notwithstanding anything to the contract in Section 4.2, Krele shall own all work product, information and data arising from the Feasibility Study regardless of whether the Option is exercised.
Ownership of Study Data. Institution shall retain and store Medical Records. The Institution and the Investigator will assign and ensure and procure that Study Staff assign to Sponsor all of their rights, title and interest, including intellectual property rights, to all Confidential Information (as defined below) and any other Study Data. 1.3.3
Ownership of Study Data. As between Novartis and Olema, (a) Novartis shall own the particular Study Data that relate exclusively to the Novartis Study Drugs (“Novartis Study Data”), and Olema shall own the particular Study Data that relate exclusively to Olema Study Drug (“Olema Study Data”), and (b) both Parties shall jointly own any and all Study Data that is not Olema Study Data or the Novartis Study Data (“Combined Therapy Study Data”). Each Party shall, and does hereby, assign, and shall cause its Affiliates to so assign, to the other Party, without additional compensation, its right, title and interest in and to any Study Data as is necessary to fully effect the foregoing ownership, and agrees to execute all instruments as may be reasonably necessary to effect same.
Ownership of Study Data. Institution shall retain and store Medical Records. The Institution will assign, and ensure and procure that Study Staff CRFs; a (iii) přijme opatření za účelem zabránění náhodného či předčasného zničení či poškození těchto dokumentů. Ani Zdravotnické zařízení, ani Zkoušející nezničí či nepovolí likvidaci jakýchkoli Zdravotních záznamů či Studijních dat a údajů bez předchozího písemného souhlasu Zadavatele. Zdravotnické zařízení uchová Zdravotní záznamy a Studijní data a xxxxx, xxxxx i veškerou dokumentaci vztahující se ke Subjektům Studie po dobu 15 let od ukončení Studie nebo předčasného ukončení klinického hodnocení, pokud Zadavatel nevydá žádné další pokyny a pokud příslušné právní předpisy nestanoví xxxxx xxxx xxxxxxxx (xxxxx xxx 00 let). Nebudou-li to vylučovat platné právní předpisy, anebo nebudou-li po uplynutí výše uvedené lhůty Studijní data a ostatní dokumentace vráceny Zadavateli na jeho žádost, je Zdravotnické zařízení oprávněno přistoupit ke skartaci dokumentů. V případě ukončení pracovněprávního poměru Zkoušejícího, odpovědnost za vedení Zdravotních záznamů a Studijních dat a údajů bude určena v souladu s příslušnými právními předpisy, avšak Zdravotnické zařízení se v xxxxxx xxxxxxx xxxxxxxxx xxxxx povinností, jež jí plynou z této Smlouvy ve vztahu k vedení Zdravotních záznamů a Studijních dat a údajů. 1.3.2 Vlastnictví Studijních dat a údajů. Zdravotnické zařízení si ponechá a bude uchovávat Zdravotní záznamy. Zdravotnické zařízení převede
Ownership of Study Data. Nektar shall own the Study Data to the extent that it relates exclusively to the Nektar Compound (“Nektar Study Data”), and BioXcel shall own the Study Data to the extent that it relates exclusively to the BioXcel Compound (“BioXcel Study Data”). Both Parties shall jointly own any Study Data that does not relate exclusively to the BioXcel Compound or the Nektar Compound (“Combined Therapy Study Data”). Each Party shall, and does hereby, assign, and shall cause its Affiliates to so assign, to the other Party, without additional compensation, such right, title and interest in and to any Study Data as is necessary to fully effect the foregoing, and agrees to execute all instruments as may be reasonably necessary to effect same. Nektar shall have the right to disclose the Combined Therapy Study Data to BMS, and BMS shall have the right to use the Combined Therapy Study Data as provided in the SCA; provided that Nektar shall not disclose any confidential information of the CPI Compound supplier CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WHERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 24B-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. in connection therewith, including any data, results or information relating solely to the CPI Compound or any pharmacokinetic information relating to the CPI Compound (to be clear, nothing in the foregoing proviso shall prohibit Nektar from disclosing the Combined Therapy Study Data to BMS on the terms provided herein).
Ownership of Study Data. BMS shall own the Study Data to the extent that it relates solely to the BMS Study Drug (“BMS Study Data”), and Recipient shall own the Study Data to the extent that it relates solely to the Recipient Study Drug (“Recipient Study Data”).
